Mechanism of Mesenchymal Stem Cells Preconditioned with IFN γ in the Treatment of Autoimmune Diseases

Authors

  • Yiru Dong QU-Drake United College, Qingdao University, 266100 Laoshan District Qingdao, China

DOI:

https://doi.org/10.54097/7qym3c13

Keywords:

Autoimmune diseases, Mesenchymal stem cells (MSCs), IFN-γ.

Abstract

Autoimmune diseases are chronic and intractable and caused by the disruption of immune tolerance mechanisms and the imbalance of immune homeostasis. Conventional treatments and targeted drugs have the limitations such as insufficient safety and low response rates. By unique advantages of immunomodulation and tissue repair, an innovative treatment, Mesenchymal stem cells (MSCs) have gradually matured. Nevertheless, they are still facing the problems like instable function and low homing efficacy in clinical translation. Interferon-γ (IFN-γ) preconditioned can effectively optimize efficacy of MSCs, with core mechanisms including:Binding to IFN-γ receptors (IFNγR) on the surface of MSCs to activate the JAK-STAT signaling pathway and trigger the transcription of immunomodulation related genes;Significantly upregulating the expression of IDO1, PD-L1, and TGF-β, which regulate the activation and function of Tregs, T cells and B cells to reestablish immune homeostasis, downregulating the expression of chemokine receptors CXCR4 and CCR7, shifting the function of MSCs from active migration to local retention and enhancing local therapeutic efficacy at lesion sites. This paper systematically organizes the activation, immunoregulatory and homing optimization mechanism of IFN-γ preconditioned MSCs, summarizes the advantages and challenges and provides a theoretical reference for basic research and clinical translation in the treatment of autoimmune diseases.

Downloads

Download data is not yet available.

References

[1] J. Deng, Y. Deng,Y. Chen, F. Bai,B. Zhang, W. Jiang, W. Wang, H. Yu, The IL-23/IL-17/NF-κB Signaling Pathway in Rheumatoid Arthritis: Molecular Mechanisms and Therapeutic Agents. Med Res Rev. 46(3), 625–671 (2026). https://doi.org/10.1002/med.70024 DOI: https://doi.org/10.1002/med.70024

[2] A. Hazrati, K. Malekpour, Z. Mirsanei, A. Khosrojerdi, N. Rahmani-Kukia, N. Heidari, A. Abbasi, S. Soudi, Cancer-associated mesenchymal stem/stromal cells: role in progression and potential targets for therapeutic approaches. Front Immunol. 14, 1280601 (2023). https://doi.org/10.3389/fimmu.2023.1280601 DOI: https://doi.org/10.3389/fimmu.2023.1280601

[3] O. Palomares, D. Elewaut, P.A. Irving, X. Jaumont, P. Tassinari, Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity? Allergy. 77(11), 3293–3308 (2022). https://doi.org/10.1111/all.15449 DOI: https://doi.org/10.1111/all.15449

[4] C.G. Bonasia, W.H. Abdulahad, A. Rutgers, P. Heeringa, N.A. Bos, B cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B cells. Cells. 10(5), 1190 (2021). https://doi.org/10.3390/cells10051190 DOI: https://doi.org/10.3390/cells10051190

[5] S.S. Tehrani, P. Mikulski, I. Abdul-Zani, J.F. Mata, W. Siwek, L..E. Jansen, STAT1 is required to establish but not maintain interferon-γ-induced transcriptional memory. EMBO J. 42(14), e112259 (2023). https://doi.org/10.15252/embj.2022112259 DOI: https://doi.org/10.15252/embj.2022112259

[6] W. Ning, S. Huang, Spatially resolved tryptophan-kynurenine niches in HNSCC: immunometabolic microdomains and therapeutic implications. Front Immunol. 17, 1756010 (2026). https://doi.org/10.3389/fimmu.2026.1756010 DOI: https://doi.org/10.3389/fimmu.2026.1756010

[7] W. Chen, TGF-β regulation of T cells. Annu Rev Immunol. 41, 483–512 (2023). https://doi.org/10.1146/annurev-immunol-101921-045939 DOI: https://doi.org/10.1146/annurev-immunol-101921-045939

[8] H.C. Hope, G. Pickersgill, P. Ginefra, N. Vannini, G.P. Cook, R.J. Salmond, TGFβ limits Myc-dependent TCR-induced metabolic reprogramming in CD8+T cells. Front Immunol. 13, 913184 (2022). https://doi.org/10.3389/fimmu.2022.913184 DOI: https://doi.org/10.3389/fimmu.2022.913184

[9] J.-H. Nam, J.H. Moon, B. Choi, G.-H. Kang, Y. Park, S.-Y. Park, T.-H. Ko, D. Shin, Y. Jung, S.-N. Kim, Y.-K. Cho, M.-S. Jeon, IFN-αand vitamin B6-induced galectin-9 promotes the immunomodulatory function of human clonal mesenchymal stem cells. Stem Cell Res Ther. 16(1), 270 (2025). https://doi.org/10.1186/s13287-025-04394-3 DOI: https://doi.org/10.1186/s13287-025-04394-3

[10] S.G. Park, J.H. An, Q. Li, H.K. Chae, S.M. Park, J.H. Lee, J.O. Ahn, W.J. Song, H.Y. Youn, Feline adipose tissue-derived mesenchymal stem cells pretreated with IFN-γenhance immunomodulatory effects through the PGE₂pathway. J Vet Sci. 22(2), e16 (2021). https://doi.org/10.4142/jvs.2021.22.e16 DOI: https://doi.org/10.4142/jvs.2021.22.e16

Downloads

Published

15-11-2026

Issue

Section

Articles

How to Cite

Dong, Y. (2026). Mechanism of Mesenchymal Stem Cells Preconditioned with IFN γ in the Treatment of Autoimmune Diseases. International Journal of Biology and Life Sciences, 17(2), 251-256. https://doi.org/10.54097/7qym3c13